Geographic Coverage: East Cambridgeshire
Cognitive Function and Ageing Study II (CFAS II)
Since the baseline of MRC CFAS there has been an increase in life expectancy, changes in major chronic disease and potentially advances in symptomatic treatments for Alzheimer’s disease and other dementias. CFAS II builds upon the design and infrastructure of MRC to investigate the implications of changes in morbidity and frailty on health itself, as well as the use of services and expenditure in health and social care on future. It also provides important baseline information on older people aged 65-84 in 2008-2011 who will reach the age of greatest frailty during the 2020’s, when the peak in the number of people aged 85 or over is expected and at a time when major therapeutic interventions for dementia could be expected to have an effect.
MRC Cognitive Function and Ageing Study (MRC CFAS)
MRC CFAS began in the late 1980s with the initial aim of investigating dementia and cognitive decline in a representative sample of more than 18,000 people aged over 65 years. The study primarily aimed to find out how common dementia and associated conditions are in England and Wales and also, how many new cases of dementia develop each year. The range of information collected in the interviews has also allowed the study to also investigate depression and physical disability in the older population in addition to looking at healthy active life expectancy. MRC CFAS ran from 1989 – 2011. Having provided estimations of dementia occurrence for the UK, CFAS was increasingly asked to provide evidence on generational change in dementia, cognition and life expectancy by the government and the public, leading to its daughter studies, CFAS II & CFAS Wales.